Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KHK | P50053 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13635124 | 0.92 | KDM2B (0.44) | KDM4EKHKALDH1A1HPGDPARP1 | |
| SCHEMBL13011465 | 0.92 | KDM2B (0.44) | KDM4EKHKALDH1A1HPGDPARP1 | |
| SCHEMBL13061928 | 0.86 | L3MBTL1 (0.51) | KDM4EALDH1A1HPGDPARP1L3MBTL1 | |
| SCHEMBL13011348 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1HPGDPARP1L3MBTL1 | |
| SCHEMBL13011412 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1HPGDPARP1L3MBTL1 | |
| SCHEMBL13011096 | 0.85 | KIF11 (0.46) | KDM4EKHKALDH1A1PARP1PTGER4 | |
| SCHEMBL3782244 | 0.84 | NPY5R (0.48) | KDM4EALDH1A1HPGDPARP1L3MBTL1 | |
| SCHEMBL4371739 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HPGDPARP1L3MBTL1 | |
| SCHEMBL13011265 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HPGDPARP1L3MBTL1 | |
| SCHEMBL13011376 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HPGDPARP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | KDM4E 731/4885KHK 3357/4885ALDH1A1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.